Gary Heimberg

Gary Heimberg

Subscribe to all posts by Gary Heimberg

Level-setting the President’s Budget Blueprint and Rx Pricing: Putting the Process and Substance in Context

Today, the President will submit the Administration’s Fiscal Year 2019 budget blueprint to Congress.  The document will set in motion an annual process to analyze the substance, business implications and prospects for various proposals.  Draft documents have already begun to circulate that suggest that both the budget and a forthcoming addendum would, if enacted, have … Continue Reading

The Dynamic Political and Public Policy Landscape in DC on Pharmaceutical Issues

The post-election period — from the lame duck congressional session to the first 100 days and beyond of a new Administration and Congress — is expected to be a time of extraordinary, if not unprecedented, public policy debate on issues that impact pharmaceutical/life sciences companies and interest groups. These issues present both significant threats and … Continue Reading

House Passes Fostering Innovation Act

This week, the U.S. House of Representatives unanimously passed the Fostering Innovation Act of 2015 (H.R. 4139), bipartisan legislation that would extend for an additional five years the current exemption for emerging growth companies from certain internal corporate financial control requirements of the Sarbanes-Oxley Act.  The bill offers relief for medical technology and other emerging … Continue Reading
LexBlog